

BName and Affiliation	Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest appropriate to role(s) in the activity
Aguirre A. de Cubas, PhD Medical University of South Carolina	Faculty	No relevant financial disclosures	NA	NA
Aristotelis Bamias, MD Medical School, University of Athens	Faculty	1. AstraZeneca, BMS, IPSEN, MSD, Pfizer 2. AstraZeneca, BMS, IPSEN, Pfizer 3. Pfizer 4. BMS, MSD, IPSEN, Pfizer	1. Non-CE Consulting 2. Contract Research 3. Educational activity support 4. Honoraria	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Ashley Ruggieri Kidney Cancer Association	Planner	1. Ownership Interest (stocks)	1. Medtronic, Merck, Thermo, CVS Health Corp, 3M, Fisher, United Health Group	All final review decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Chair.
Axel Bex, MD, PhD The Netherlands Cancer Institute	Faculty, Peer Reviewer	1. Pfizer 2. Roche/ Genentech, BMS	1. Contract Research Restricted Educational Grant 2. Other: Steering Committee for Adjuvant Trials	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning. All final review decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Chair.

<p>Bernard Escudier, MD The Netherlands Cancer Institute</p>	<p>Faculty, Peer Reviewer</p>	<ol style="list-style-type: none"> 1. Bristol Myers Squibb 2. AVEO, Bristol Myers Squibb, Eisai, Ipsen, Oncorena, Pfizer 3. Bristol Myers Squibb, Eisai, Ipsen, Oncorena, and Pfizer 4. Bristol Myers Squibb, Ipsen, MSD 	<ol style="list-style-type: none"> 1. Institutional Research Grant Support 2. Consulting Fees 3. Honoraria 4. Travel Support 	<p>Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.</p> <p>All final review decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Chair.</p>
<p>Camillo Porta, MD IRCCS San Matteo University Hospital Foundation</p>	<p>Faculty</p>	<ol style="list-style-type: none"> 1. Angelini Pharma, BMS, Eisai, EUSA Pharma, General Electric, Ipsen, MSD, Novartis, Pfizer 	<ol style="list-style-type: none"> 1. Consultant and/or Speaker 	<p>Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.</p>
<p>Charles Drake, MD, PhD Columbia University Medical Center</p>		<ol style="list-style-type: none"> 1. Employed by Janssen Research and Development 2. Columbia University 3. Johns Hopkins University 4. Co-inventor on LAG-3 IP licensed from Johns Hopkins to BMS 	<ol style="list-style-type: none"> 1. Employment relationship 2. Adjunct appointment with ongoing clinical activities 3. Adjunct appointment with ongoing research collaborations 4. Associated royalties 	<p>Unable to mitigate disclosed relevant financial relationship, CE credit was removed from this presentation.</p>
<p>Christian Beisland, MD, PhD University of Bergen</p>	<p>Planning Committee Member, Faculty, Peer Reviewer</p>	<p>No relevant financial disclosures</p>	<p>NA</p>	<p>NA</p>

Cristiane Decat Bergerot, PhD Centro de Cancer de Brasília, Instituto Unity de Ensino e Pesquisa	Faculty	No relevant financial disclosures	NA	NA
Cristina Suárez Rodríguez, MD Vall d'Hebron University Hospital	Faculty, Peer Reviewer	1. Astellas Pharm, BMS, Hoffman-La Roche, LTD 2. BMS, Hoffman-La Roche, LTD, Ipsen, Pfizer, S.L.U 3. AB Science, Aragon, Astellas, AstraZeneca, Bayer, Blueprint, Boehringer, BMS, Clovis, Exelixis, Genentech, Hoffman- La Roche, LTD, Novartis, Pfizer, Sanofi	1. Non-CE Consulting 2. Non-CE Speakers Bureau 3. Contract Research	Content was reviewed by a non- conflicted member of the planning committee to ensure that it is not commercially biased, was fair- balanced, and is based on scientific evidence and/or clinical reasoning. All final review decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Chair.
Daniel George, MD Duke University Medical Center	Faculty, Peer Reviewer	1. Astellas, AZ, Bayer, BMS, Constellation, Exelixis, Flatiron, IdoOncology, Janssen, Merck, Michael 2. Bayer, Exelixis, Sanofi 3. Astellas, AZ, BMS, Calithera, Exelixis, Janssen, Novartis, Pfizer, Sanofi 4. AACR, AZ-CAP1281, Capio, CAHO	1. Non-CE Consulting 2. Non-CE Speakers Bureau 3. Contract Research 4. Other: Senior Editor, Steering Committee, Scientific Advisory Board, Co- Editor-In-Chief	Content was reviewed by a non- conflicted member of the planning committee to ensure that it is not commercially biased, was fair- balanced, and is based on scientific evidence and/or clinical reasoning. All final review decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Chair.
David Braun, MD, PhD Yale School of Medicine	Faculty	1 Adnovate Strategies, MDedge, Exelixis, Cancer Expert Now, Cancer Network, Catenion 2. Exelixis 3. Exelixis, AVEO 4. LM Education and Exchange	1. Non-CE Consulting 2. Research grants 3. Advisory board 4. Honoraria	Content was reviewed by a non- conflicted member of the planning committee to ensure that it is not commercially biased, was fair- balanced, and is based on scientific evidence and/or clinical reasoning.

Dena Battle KCCure	Faculty	No relevant financial disclosures	NA	NA
Désirée Louise Dräger, MD University of Rostock	Faculty	No relevant financial disclosures	NA	NA
Elfriede Noessner, PhD Helmholtz Zentrum München	Faculty	<ol style="list-style-type: none"> 1. Medigene Immunotherapeutics GmbH 2. Phio Pharmaceutical Corp 3. Helmholtz Zentrum Munchen, licensed to Medigene AG 4. Definiens AG, Roche Pharma AG, AstraZeneca AG, VisioPharm 5. Roche Pharma AG, Hexal, Novartis, Solution Akademie GmbH, IPSEN Pharma GmbH 	<ol style="list-style-type: none"> 1. Contracted research 2. Research support 3. Receipt of Intellectual Property Rights/Patent Holder 4. Advisory activity 5. Honorarium 	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Elizabeth P. Henske, MD Dana-Farber Cancer Institute	Faculty	No relevant financial disclosures	NA	NA
Eva Compérat, MD, PhD L'Assistance Publique-Hôpitaux de Paris, Hôpital Tenon	Faculty	<ol style="list-style-type: none"> 1. Janssen 2. IBEX 3. Janssen, IBEX 	<ol style="list-style-type: none"> 1. Non-CE Consulting 2. Contract Research 3. Royalty 	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Gabriel Malouf, MD, PhD Institut de Cancérologie de Strasbourg-Europe, Strasbourg University	Planning Committee Member, Faculty	1. Pfizer, MSD, Ipsen, BMS	1. Non-CE Consulting	<p>All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Chair.</p> <p>Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-</p>

				balanced, and is based on scientific evidence and/or clinical reasoning.
Gennady Bratslavsky, MD SUNY Upstate	Faculty	1. Johnson & Johnson, Merck 2. Aptamatrix 3. Taurus Diagnostics	1. Non-CE Consulting 2. Salary (CMO) 3. Other (Co-founder)	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Giuseppe Procopio, MD Fondazione IRCCS Istituto Nazionale Tumori	Faculty	1. AstraZeneca, Bayer, BMS, Ipsen, Janssen, MSD, Novartis, Eisai, Merck, Pfizer	1. Honoraria for Consulting or Advisory Role	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Grant Stewart, MD University of Cambridge	Faculty	1. Pfizer, AstraZeneca, Intuitive Surgical 2. Pfizer 3. Pfizer, Merck, EUSA Pharma	1. Educational grants/funding 2. Travel Expenses 3. Honoraria/Speaker fees	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Gretchen Vaughn, BBA Kidney Cancer Association	Planner	No relevant financial disclosures	NA	NA
Guillermo de Velasco, MD, PhD University Hospital 12 de Octubre	Planning Committee Member, Faculty, Peer Reviewer	1. Bayer, BMS, Ipsen, Merck, MSD, Pfizer, Roche 2. Astellas, BMS, MSD, Pfizer, USA Pharma 3. BMS, Ipsen, Roche	1. Non-CE Consulting 2. Non-CE Speakers Bureau 3. Contract Research	All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Chair. Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning. All final review decisions concerning content, learning objectives, and

				evaluation questions were made by the non-conflicted Planning Committee Chair.
Heather Tarbox, MPH The France Foundation	Planner	No relevant financial disclosures	NA	NA
Holger Moch, MD University Hospital Zurich	Faculty	1. Roche 2. Bayer, Janssen, Amgen, AZ, J&J	1. Research Funding 1. Advisory boards	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Ian Frew, PhD, BSc University Medical Center Freiburg	Faculty	1. Merck Healthcare	1. Contract Research	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Janet Brown, BMedSci, MBBS, MSc, MD, FRCP The University of Sheffield	Faculty	1. AstraZeneca 2. BMS, Novartis 3. Ipsen	1. Academic Grant 2. Advisory Board Fees 3. Travel to International Meeting/Advisory board fees	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Jas Chahal, PhD The France Foundation	Planner	No relevant financial disclosures	NA	NA
Jeanette Stensgaard, MBA, CMP Kidney Cancer Association	Planner	No relevant financial disclosures	NA	NA
Jennifer Vitek Kidney Cancer Association	Planner	No relevant financial disclosures	NA	NA
John Haanen, MD, PhD Netherlands Cancer Institute	Faculty	1. BioNTech, BMS, Ipsen, Eisai, Instill Bio, Iovance Bio, MSD, Merck Serono, Novartis, Pfizer, PokeAcel, Roche, Sanofi, T-Knife 2. Neogene Tx	1. Advisory Roles (all paid to institute) 2. Paid Advisory Role	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.

		<p>3. Amgen, Asher Bio, BioNTech, BMS, MSD, Novartis, Neogene TX</p> <p>4. Neogene Tx</p> <p>5. ESMO IOTECH</p>	<p>3. Grant Support (institute)</p> <p>4. Stock Options</p> <p>5. Editor-in-Chief</p>	
Jose Karam, MD MD Anderson Cancer Center	Faculty	<p>1. Pfizer, Merck, Johnson & Johnson</p> <p>2. Merck, Roche/Genetech, Mira, Elypta</p> <p>3. MedTek, ROM Teck</p>	<p>1. Non-CE Consulting</p> <p>2. Contract Research</p> <p>3. Ownership interests (stocks)</p>	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Katharina Beyer King's College London	Faculty	No relevant financial disclosures	NA	NA
Katy Beckermann, MD, PhD Vanderbilt University	Faculty	<p>1. Aravive, Aveo, BMS, Exelexis, Astellas</p> <p>2. Aravive, Arrowhead, Aveo, BMS, Exelexis, Merck</p> <p>3. Merck, BMS-IASLC-LCFA</p>	<p>1. Consultant</p> <p>2. Clinical trial research to the institution</p> <p>3. Research grant to the institution</p>	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Kendall Monroe Kidney Cancer Association	Planner	No relevant financial disclosures	NA	NA
Kristen Brady The France Foundation	Planner	No relevant financial disclosures	NA	NA
Lars Lund, MD, PhD University of Southern Denmark	Planning Committee Member, Faculty, Peer Reviewer	No relevant financial disclosures	NA	NA
Laurence Albiges, MD, PhD Institut Gustave-Roussy	Faculty	1. Astellas, AstraZeneca, BMS, Ipsen, Janssen, Merck & Co, MSD, Novartis, Pfizer, Eisai	1. Non-CE Consulting	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-

		2. BMS	2. Contract Research	balanced, and is based on scientific evidence and/or clinical reasoning.
Lisa Pickering, MD, PhD The Royal Marsden NHS Foundation Trust	Faculty	1. BMS, EUSA, MSD, Pfizer 2. Ipsen, Pfizer	1. Advisory Bureau 2. Speaker fees	NA
Marta Scorsetti, MD University of Milan	Faculty	No relevant financial disclosures	NA	NA
Michael Staehler, MD, PhD Ludwig-Maximilians University of Munich	Planning Committee Member, Faculty, Peer Reviewer	1. Pfizer, GlaxoSmithKline, Novartis, Bayer, Roche, Aveo, EUSA Pharm, Astellas, Ipsen, Exelixis, Pelloton, Eisai, BMS, MSD, Apogepha 2. Pfizer, GlaxoSmithKline, AVEO, Novartis, Bayer, EUSA Pharm, Astellas, Ipsen, Exelixis, Pelloton, Eisai, BMS, MSD, Apogepha 3. Pfizer, GlaxoSmithKline, AVEO, BMS, Novartis, Bayer, Roche/Genentech, Immatix, Wilex, Ipsen, Exelixis, Eisai	1. Non-CE Consulting 2. Non-CE Speakers Bureau/Honoraria 3. Contract Research	All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Chair. Content was reviewed by a non- conflicted member of the planning committee to ensure that it is not commercially biased, was fair- balanced, and is based on scientific evidence and/or clinical reasoning. All final review decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Chair.
Naveen Vasudev, MD University of Leeds	Faculty	1. BMS, Pfizer Merck, 4D Pharma 2. BMS, Ipsen, EUSA Pharma 3. BMS	1. Advisory Boards 2. Speaker fees 3. Contract Research	Content was reviewed by a non- conflicted member of the planning committee to ensure that it is not commercially biased, was fair- balanced, and is based on scientific evidence and/or clinical reasoning.
Patrick Harty, PhD The France Foundation	Planner, Peer Reviewer	No relevant financial disclosures	NA	NA
Pedro Barata, MD, MSc Tulane University	Faculty	1. Astellas; Eisai; Janssen, EMD Serono; Dendreon; Pfizer, Seattle	1. Non-CE Consulting	Content was reviewed by a non- conflicted member of the planning committee to ensure that it is not

		Genetics, BMS, Bayer, Guardant Health 2. Bayer, Caris, Myovant 3. AstraZeneca, Merck, AVEO Oncology 4. BlueEarth Diagnostics, Merck	2. Non-CE Speakers Bureau 3. Contract Research 4. Research Grant	commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Rachel Giles, MD University Medical Center Utrecht	Faculty	No relevant financial disclosures	NA	NA
Radha Chitale Kidney Cancer Association	Planner	No relevant financial disclosures	NA	NA
Ronan Flippot, MD, MSc Dana-Farber Cancer Institute	Faculty	1. BMS, MSD, Astellas 2. Janssen, Ipsen 3. Ipsen	1. Honoraria 2. Consulting 3. Travel	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Sallie McAdoo, MS, CGC Kidney Cancer Association	Planner	No relevant financial disclosures	NA	NA
Samra Turajlic, MD The Francis Crick Institute/ The Royal Marsden Hospital	Planning Committee Chair, Faculty, Peer Reviewer	No relevant financial disclosures	NA	NA
Stephanie Kroeze, MD, PhD University Hospital Zurich	Faculty	1. Bayer	1. Non-CE Speakers Bureau	Relationship ended in December 2021.
Theresa Junker, RN, PhD Odense University Hospital/ Svendborg Hospital	Faculty	No relevant financial disclosures	NA	NA
Thomas Powles, MBBS, MRCP, MD Bart's Cancer Institute	Planning Committee Member, Faculty,	1. AstraZeneca, BMS, Exelixis, Incyte, Ipsen, Merck, MSD, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson &	1. Non-CE Consulting or Honoraria	All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Chair.

	Peer Reviewer	Johnson, Merck, Eisai, Roche, Mashup Ltd 2. AstraZeneca, BMS, Exelixis, Ipsen, Merck, MSD, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, Eisai, Roche 3. Roche, Pfizer, MSD, AstraZeneca, Ipsen	2. Contract Research 3. Travel/Accommodations/Expenses	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning. All final review decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Chair.
Tian Zhang, MD, MHS UT Southwestern Medical Center	Faculty	1. Acerta, Novartis, Merrimack, Abbvie/StemCentrx, Merck, Regeneron, Mirati Therapeutics, Janssen, Astra Zeneca, Pfizer, OmniSeq, Personal Genome Diagnostics, Astellas 2. Merck, Exelixis, Sanofi-Aventis, Janssen, Astra Zeneca, Pfizer, Amgen, BMS, Pharmacyclics, SeaGen, Calithera, Dendreon, QED Therapeutics, Eisai, Aveo Pharmaceuticals, Bayer, Eli Lilly 3. Pfizer, MJH Associates, Vaniam, Aptitude Health, PeerView, Clinical Care Options	1. PI/Research Funding 2. Advisory Board 3. Consultant	Relationships with Novartis (Contract Research), Merrimack (Contract Research), Abbvie/Stemcentrx (Research Funding to Duke) Regeneron (Contracted Research), Mirati Therapeutics (Contracted Research), Omniseg (Contracted Research), PGDx (Contracted Research), Amgen (Consulting Fees), Dendreon (Consulting Fees), Sanofi-Aventis (Speakers Bureau) ended prior to January of 2022. Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Tim O'Brien, MA, DM, FRCS Guy's and St. Thomas' NHS Foundation Trust	Faculty	No relevant financial disclosures	NA	NA
Umberto Capitanio, MD YAU-EAU Università Vita-Salute	Faculty	No relevant financial disclosures	NA	NA

San Raffaele				
Viktor Grünwald, MD, PhD University-Hospital Essen	Faculty, Peer Reviewer	<ol style="list-style-type: none"> 1. BMS, MSD, Eisais, Ipsen, Debiopharm, Novartis, Merck Healthcare, Nanobiotix, Janssen, Pfizer 2. AstraZeneca, Apogepha, BMS, MSD, Merck Healthcare, Eisai, EUSA Pharm, Roche, Ipsen, Novartis, Janssen, Pfizer, AAA/Novartis, Ono Pharmaceuticals 3. Pfizer (Wyeth), BMS, MSD, Novartis, AstraZeneca 4. SeaGen, Ipsen, Eisai, Merck, MSD, BMS 	<ol style="list-style-type: none"> 1. Non-CE Consulting 2. Non-CE Speakers Bureau/ Honoraria 3. Financial Research Support 4. Contract Research 	<p>Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.</p> <p>All final review decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Chair.</p>
Will Ince, FRCR, MRCP, MRCGP, MB, BS Addenbooke's Hospital	Faculty	No relevant financial disclosures	NA	NA